Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10345 in treatment-resistant depression
NCT05196971Phase 1Completed
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Oct 2021
- Primary completion
- Apr 2022
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in treatment-resistant depression (TRD) comparing HS-10345 84mg with Placebo (2 arms). Primary endpoints: Number of participants with adverse events (AEs) and Serious Adverse Events (SAEs) up to 7 weeks, Columbia-Suicide Severity Rating Scale Total Score at Day 15 and 3 more. Started Oct 2021; status: completed.
02
Drugs
HS-10345
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT05196971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05196971.